REFERENCES
1. Yau T, Galle PR, Decaens T, et al. ; CheckMate 9DW investigators. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet. 2025;405:1851-64.
2. Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1:EVIDoa2100070.
3. Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76:862-73.
4. Qin S, Chan SL, Gu S, et al. ; CARES-310 Study Group. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402:1133-46.
5. Rimassa L, Chan SL, Sangro B, et al. Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC. J Hepatol. 2025;83:899-908.
6. Chen D, Xu G, Fan A, et al. Molecular characteristics of fatty acid metabolic reprogramming in hepatocellular carcinoma and their implications for immunotherapy. Hepatoma Res. 2026;12:5.
7. Ruan Z, Sun X. Metabolic reprogramming and the tumor microenvironment in hepatocellular carcinoma: mechanisms and therapeutic targeting. Hepatoma Res. 2026;12:9.
8. Pang N, Shi J, Qin L, et al. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin. J Hematol Oncol. 2021;14:118.
9. Xie M, Lin Z, Ji X, et al. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2. J Hepatol. 2023;79:109-25.
10. Liang Z, Long X, Xiong Z, et al. Tumor cells metabolically resist immune-checkpoint therapy by macrophage efferocytosis-mediated fatty acid recycling. Cancer Cell. 2026;44:1235-54.e11.
11. Han H, Ma J, Wang J, Liu Y. Immune microenvironment and immunotherapy strategies in MAFLD-related hepatocellular carcinoma. Hepatoma Res 2025;11:24.
12. Li M, Song W, Wu Y, Lin H, Liu W, Chi J. Rewiring the tumor microenvironment in hepatocellular carcinoma: mechanism-driven integration of immunotherapy and locoregional strategies. Hepatoma Res 2026;12:3.
